DENVER, CO–(Marketwired – Aug 8, 2016) – American Cannabis Company, Inc. (OTCQB: AMMJ) (the “Company”), a full-service business-to-business consulting solutions provider, and seller of ancillary products to the cannabis industry, today announced that one of the Company’s Canadian-based clients secured approval for their medical cannabis business application. For this specific client, American Cannabis Company, Inc. developed the standard operating procedures that were evaluated by Health Canada, as part of the licensing process.
The standard operating procedures focus on the creation of a protocol-based workflow in line with best operating practices. ACC expects to leverage this contract to secure additional revenues through long-term consulting agreements, potential sales of ancillary products and services to aid cultivation operations.
Corey Hollister, president and CEO, American Cannabis Company, commented: “The Canadian market is extremely exciting to operate in as it provides ACC the opportunity to interface with Health Canada, a federal level agency. Achieving success for our client in Canada paves the road for the continued advancement in how the US state level markets operate. This is the second client we have assisted in the development of compliant standard operating procedures for Health Canada.”
About American Cannabis Company, Inc.:
American Cannabis Company, Inc. offers end-to-end solutions to existing and aspiring participants in the cannabis industry. We utilize our industry expertise to provide business planning and market assessment services, assist state licensing procurement, create business infrastructure and operational best practices. Through our two vertically integrated businesses, American Cannabis Consulting and American Cultivator Company, a group purchasing organization, we support our clients from concept to creation to commercialization to on-going operations.
For more information, please visit: www.americancannabiscompanyinc.com.
Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward- looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.